Reasons to Add Fresenius Medical Stock to Your Portfolio Now

Fresenius Medical Care AG & Co. FMS is well-poised for growth on the back of strategic acquisitions and partnerships and a solid global foothold. However, a tough regulatory environment remains a concern.Shares of this Zacks Rank #1 (Strong Buy) company have risen 21.7% year to date against the industry’s decline of 9.1%. The S&P 500 Index has increased 5.2% in the same time frame.The company, with a market capitalization of $16.25 billion, is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Its bottom line is anticipated to improve 19.2% over the next five years. FMS’ earnings beat estimates in all the trailing four quarters, delivering an average surprise of 6.6%.Image Source: Zacks Investment ResearchReasons Favoring FMS’s GrowthStrong Global Foothold: Fresenius Medical maintains a robust global footprint across North America, EMEA, Asia Pacific, and Latin America, driven by both organic expansion and strategic acquisitions. The company entered the Israeli dialysis market and reinforced its position in India by acquiring an 85% stake in Sandor Nephro Services. It also leverages public-private partnerships to access new markets. Despite the challenges posed by the pandemic, Fresenius Medical has sustained consistent organic growth, with notable contributions from EMEA, Asia Pacific, and Latin America, particularly during the third quarter of 2024.Strategic Acquisitions & Partnerships: Fresenius Medical has leveraged strategic acquisitions and partnerships to drive its growth strategy. It acquired NxStage Medical for $30 per share, expecting earnings accretion within three years and annual pre-tax savings of $80 million to $100 million. The company’s 2025 growth strategy includes the merger of Fresenius Health Partners, InterWell Health, and Cricket Health to manage 270,000 patients with kidney disease and associated medical costs of $11 billion. Additionally, it expanded its home dialysis market through a distribution deal with JMS Co., Ltd. in Japan and extended agreements with DaVita and Aetna to enhance patient access to home hemodialysis and value-based care.Strong Q1 Results: FMS exited the first quarter with mixed results, as earnings surpassed but revenue missed the Zacks Consensus Estimate. Growth in the Care Enablement segment was supported by strong pricing momentum. The FME25 transformation program continued to progress, delivering EUR 68 million in sustainable savings during the quarter, along with one-time related costs of EUR 28 million. The company reaffirmed its target of EUR 180 million in additional annual savings by 2025, totaling EUR 750 million. Ongoing divestments of non-core and dilutive assets are expected to sharpen focus on core categories and enhance the company’s cash position.A Factor That May Offset FMS’s GainsTough Regulatory Environment: Fresenius Medical operates in a highly regulated environment, subject to stringent legal and antitrust requirements across various countries. Non-compliance can result in severe penalties, loss of certifications, product recalls, or even business restrictions. Regulatory changes, especially in reimbursement policies, could impact its business model and strategy. Additionally, international exposure presents challenges in enforcing trade receivables, with some countries' debt issues posing potential risks. While short-term regulatory risks remain low, they could become a medium-term concern.Estimate TrendThe Zacks Consensus Estimate for 2025 revenues is pegged at $21.91 billion, indicating 4.8% year-over-year growth. The consensus mark for earnings is pinned at $2.21 per share, implying growth of 33.1% from the year-ago level. The earnings estimates have improved 6 cents in the past 30 days.Other Key PicksSome other top-ranked stocks in the broader medical space are Hims & Hers Health, Inc. HIMS, Cencora, Inc. COR and Integer Holdings Corporation ITGR.Hims & Hers, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 36.5%. HIMS’ earnings surpassed estimates in two of the trailing four quarters, missed once and met in the other, the average surprise being 19.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.Hims & Hers’ shares have surged 99.2% compared with the industry’s 37.1% growth in the past year.Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%.Cencora’s shares have rallied 23.9% against the industry’s 16.9% decline in the past year.Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.Integer Holdings’ shares have gained 4.9% against the industry’s 13% decline in the past year.Higher. Faster. Sooner. Buy These Stocks NowA small number of stocks are primed for a breakout, and you have a chance to get in before they take off.At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We’ve combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month.You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days.Download the report free now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks